Xu Sun, Xiaona Meng, Qike Wang, Lu Zhang, Xiaolin Yu, He Zhang, Huaimin Liu
{"title":"Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer with <i>BRAF</i>-mutations: a retrospective study.","authors":"Xu Sun, Xiaona Meng, Qike Wang, Lu Zhang, Xiaolin Yu, He Zhang, Huaimin Liu","doi":"10.62347/MVNL2093","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To characterize the clinical features of non-small cell lung cancer (NSCLC) harboring BRAF mutations and to evaluate the effects of first-line chemotherapy combined with immunotherapy versus targeted therapy.</p><p><strong>Methods: </strong>We retrospectively reviewed patients with BRAF-mutated NSCLC diagnosed between January 2017 and June 2023 at the Affiliated Cancer Hospital of Zhengzhou University. A total of 120 patients were included, with an overall BRAF mutation frequency of 0.9%. Among the mutations detected, the Val600Glu (V600E) substitution constituted 54.2% of cases. Clinical characteristics were compared between V600E and non-V600E subgroups, and treatment efficacies were analyzed.</p><p><strong>Results: </strong>Ninety-five patients received first-line treatment. The overall median progression-free survival (mPFS) was 8.77 months, and the median overall survival (mOS) was 13.30 months. First-line chemotherapy combined with immunotherapy resulted in longer mPFS (17.17 vs. 9.03 months, P = 0.573) and mOS (17.50 vs. 16.07 months, P = 0.376) compared with targeted therapy using BRAF and MEK inhibitors. In addition, patients with V600E mutations exhibited a trend toward longer mPFS compared to those with non-V600E mutations (9.73 vs. 6.77 months, P = 0.244).</p><p><strong>Conclusions: </strong>Chemotherapy combined with immunotherapy may represent a promising first-line treatment strategy for NSCLC patients with BRAF mutations. Although the number of patients receiving subsequent lines of treatment was limited and their prognosis poor, a regimen of BRAF and MEK inhibitors appeared to offer therapeutic advantages in this setting.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3533-3545"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432574/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/MVNL2093","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To characterize the clinical features of non-small cell lung cancer (NSCLC) harboring BRAF mutations and to evaluate the effects of first-line chemotherapy combined with immunotherapy versus targeted therapy.
Methods: We retrospectively reviewed patients with BRAF-mutated NSCLC diagnosed between January 2017 and June 2023 at the Affiliated Cancer Hospital of Zhengzhou University. A total of 120 patients were included, with an overall BRAF mutation frequency of 0.9%. Among the mutations detected, the Val600Glu (V600E) substitution constituted 54.2% of cases. Clinical characteristics were compared between V600E and non-V600E subgroups, and treatment efficacies were analyzed.
Results: Ninety-five patients received first-line treatment. The overall median progression-free survival (mPFS) was 8.77 months, and the median overall survival (mOS) was 13.30 months. First-line chemotherapy combined with immunotherapy resulted in longer mPFS (17.17 vs. 9.03 months, P = 0.573) and mOS (17.50 vs. 16.07 months, P = 0.376) compared with targeted therapy using BRAF and MEK inhibitors. In addition, patients with V600E mutations exhibited a trend toward longer mPFS compared to those with non-V600E mutations (9.73 vs. 6.77 months, P = 0.244).
Conclusions: Chemotherapy combined with immunotherapy may represent a promising first-line treatment strategy for NSCLC patients with BRAF mutations. Although the number of patients receiving subsequent lines of treatment was limited and their prognosis poor, a regimen of BRAF and MEK inhibitors appeared to offer therapeutic advantages in this setting.
期刊介绍：
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
